Skip to content

Back to team

Nancy Shulman

Chief Medical Officer

Nancy Shulman has over 20 years of clinical development experience. Prior to Bluejay, she worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was VP of translational medicine. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4 studies, including extensive experience in the virology/hepatology disease area, and also in immunology and oncology. She has been a part of multiple INDs and was a key leader on the approvals of the HCV antivirals Viekira Pak®, Viekirax® and Mavyret®.

Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases. She holds a BA in Biochemistry with a minor in Chinese from the University of Texas at Austin and an MD from the University of Kansas. She completed her residency in internal medicine and pediatrics at the University of Chicago and her infectious disease fellowship at Stanford.

Keting Chu

Founder, Chief Executive Officer and Chairman of the Board

Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close $550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was previously a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for $1.5B, Kite by Gilead for $12B and Stemline by Menarini for $677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that keting led the team from discovery to phase I clinical trials are in phase II and III testing now.

Keting received her MD in Sun Yat-Sen Medical University where she specialized in infectious diseases in China, and Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.